{"id":6992,"date":"2014-09-25T18:42:57","date_gmt":"2014-09-25T18:42:57","guid":{"rendered":"https:\/\/www.nicox.com\/nicox-finalise-les-acquisitions-de-doliage-et-du-programme-de-developpement-dun-collyre-antiviral-a-base-de-carragelose\/"},"modified":"2014-09-25T18:42:57","modified_gmt":"2014-09-25T18:42:57","slug":"nicox-finalise-les-acquisitions-de-doliage-et-du-programme-de-developpement-dun-collyre-antiviral-a-base-de-carragelose","status":"publish","type":"post","link":"https:\/\/www.nicox.com\/fr\/nicox-finalise-les-acquisitions-de-doliage-et-du-programme-de-developpement-dun-collyre-antiviral-a-base-de-carragelose\/","title":{"rendered":"Nicox finalise les acquisitions de Doliage et du programme de d\u00e9veloppement d\u2019un collyre antiviral \u00e0 base de Carrag\u00e9lose\u00ae"},"content":{"rendered":"<div>Sophia Antipolis, France.<\/div>\n<div>\u00a0<\/div>\n<div><strong>Nicox S.A<\/strong>. (NYSE Euronext Paris : COX) annonce aujourd\u2019hui la r\u00e9alisation d\u00e9finitive de l\u2019acquisition de Doliage, une soci\u00e9t\u00e9 pharmaceutique fran\u00e7aise priv\u00e9e sp\u00e9cialis\u00e9e en ophtalmologie. Cette acquisition s\u2019inscrit dans la strat\u00e9gie de Nicox d\u2019\u00e9tablir une infrastructure commerciale dans les cinq principaux march\u00e9s europ\u00e9ens et apporte \u00e0 Nicox une entit\u00e9 \u00e9tablie et rentable sur le march\u00e9 fran\u00e7ais de l\u2019ophtalmologie.<\/div>\n<div>\u00a0<\/div>\n<div>Pour plus d\u2019informations, veuillez consulter les communiqu\u00e9s suivants :<\/div>\n<div>\u00a0<\/div>\n<ul>\n<li>Communiqu\u00e9 de presse du 16 septembre 2014 :\u00a0<a class=\"nx-file\" href=\"https:\/\/www.nicox.com\/assets\/files\/pr2014091601fr.pdf\">Nicox poursuit son expansion en ophtalmologie en Europe avec l\u2019acquisition du fran\u00e7ais Doliage<\/a><\/li>\n<li>Communiqu\u00e9 de presse du 25 septembre 2014 (Art. 12 de l\u2019instruction AMF n\u00b02005-11) :\u00a0<a class=\"nx-file\" href=\"https:\/\/www.nicox.com\/assets\/files\/pr2014092502fr.pdf\">Emission par Nicox de 2 235 134 actions en r\u00e9mun\u00e9ration de l&rsquo;apport de la totalit\u00e9 du capital de la soci\u00e9t\u00e9 Laboratoires Doliage<\/a><\/li>\n<\/ul>\n<div>La Soci\u00e9t\u00e9 annonce \u00e9galement la r\u00e9alisation d\u00e9finitive de l\u2019acquisition d\u2019un programme de d\u00e9veloppement d\u2019un collyre antiviral \u00e0 base de Carrag\u00e9lose\u00ae aupr\u00e8s de la soci\u00e9t\u00e9 autrichienne Marinomed Biotechnologie GmbH. Cette acquisition apporte \u00e0 Nicox un produit ophtalmique antiviral innovant qui pourrait \u00eatre mis sur le march\u00e9 en Europe d\u2019ici deux ans, sous r\u00e9serve de marquage CE, pour la prise en charge de la conjonctivite virale. Selon les termes de l\u2019accord, Nicox a acquis les droits du programme de d\u00e9veloppement du collyre antiviral \u00e0 base de Carrag\u00e9lose\u00ae via l\u2019acquisition d\u2019AVEye Biotechnologie GmbH, une filiale de Marinomed d\u00e9tenant l\u2019int\u00e9gralit\u00e9 du programme de d\u00e9veloppement.<\/div>\n<div>\u00a0<\/div>\n<div>Pour plus d\u2019informations, veuillez consulter les communiqu\u00e9s suivants :<\/div>\n<div>\u00a0<\/div>\n<ul>\n<li>Communiqu\u00e9 de presse du 16 septembre 2014 :\u00a0<a class=\"nx-file\" href=\"https:\/\/www.nicox.com\/assets\/files\/pr2014091602fr.pdf\">Nicox acquiert le programme de d\u00e9veloppement d\u2019un collyre antiviral \u00e0 base de Carrag\u00e9lose\u00ae<\/a><\/li>\n<li>Communiqu\u00e9 de presse du 25 septembre 2014 (Art. 12 de l\u2019instruction AMF n\u00b02005-11) :\u00a0<a class=\"nx-file\" href=\"https:\/\/www.nicox.com\/assets\/files\/pr2014092503fr.pdf\">Emission par Nicox de 1 240 636 actions en r\u00e9mun\u00e9ration de l&rsquo;apport de la totalit\u00e9 du capital de la soci\u00e9t\u00e9 AVEye Biotechnologie GmbH<\/a><\/li>\n<\/ul>\n<div>\u00a0<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Sophia Antipolis, France. \u00a0 Nicox S.A. (NYSE Euronext Paris : COX) annonce aujourd\u2019hui la r\u00e9alisation d\u00e9finitive de l\u2019acquisition de Doliage, une soci\u00e9t\u00e9 pharmaceutique fran\u00e7aise priv\u00e9e sp\u00e9cialis\u00e9e en ophtalmologie. Cette acquisition s\u2019inscrit dans la strat\u00e9gie de Nicox d\u2019\u00e9tablir une infrastructure commerciale dans les cinq principaux march\u00e9s europ\u00e9ens et apporte \u00e0 Nicox une entit\u00e9 \u00e9tablie et rentable [&hellip;]<\/p>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[32,16],"tags":[],"class_list":["post-6992","post","type-post","status-publish","format-standard","hentry","category-actualites","category-actualites-et-media"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nicox finalise les acquisitions de Doliage et du programme de d\u00e9veloppement d\u2019un collyre antiviral \u00e0 base de Carrag\u00e9lose\u00ae - Nicox<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.nicox.com\/fr\/nicox-finalise-les-acquisitions-de-doliage-et-du-programme-de-developpement-dun-collyre-antiviral-a-base-de-carragelose\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nicox finalise les acquisitions de Doliage et du programme de d\u00e9veloppement d\u2019un collyre antiviral \u00e0 base de Carrag\u00e9lose\u00ae - Nicox\" \/>\n<meta property=\"og:description\" content=\"Sophia Antipolis, France. \u00a0 Nicox S.A. (NYSE Euronext Paris : COX) annonce aujourd\u2019hui la r\u00e9alisation d\u00e9finitive de l\u2019acquisition de Doliage, une soci\u00e9t\u00e9 pharmaceutique fran\u00e7aise priv\u00e9e sp\u00e9cialis\u00e9e en ophtalmologie. Cette acquisition s\u2019inscrit dans la strat\u00e9gie de Nicox d\u2019\u00e9tablir une infrastructure commerciale dans les cinq principaux march\u00e9s europ\u00e9ens et apporte \u00e0 Nicox une entit\u00e9 \u00e9tablie et rentable [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.nicox.com\/fr\/nicox-finalise-les-acquisitions-de-doliage-et-du-programme-de-developpement-dun-collyre-antiviral-a-base-de-carragelose\/\" \/>\n<meta property=\"og:site_name\" content=\"Nicox\" \/>\n<meta property=\"article:published_time\" content=\"2014-09-25T18:42:57+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-finalise-les-acquisitions-de-doliage-et-du-programme-de-developpement-dun-collyre-antiviral-a-base-de-carragelose\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-finalise-les-acquisitions-de-doliage-et-du-programme-de-developpement-dun-collyre-antiviral-a-base-de-carragelose\\\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"Nicox finalise les acquisitions de Doliage et du programme de d\u00e9veloppement d\u2019un collyre antiviral \u00e0 base de Carrag\u00e9lose\u00ae\",\"datePublished\":\"2014-09-25T18:42:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-finalise-les-acquisitions-de-doliage-et-du-programme-de-developpement-dun-collyre-antiviral-a-base-de-carragelose\\\/\"},\"wordCount\":344,\"publisher\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\"},\"articleSection\":[\"Actualit\u00e9s\",\"Actualit\u00e9s et M\u00e9dia\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-finalise-les-acquisitions-de-doliage-et-du-programme-de-developpement-dun-collyre-antiviral-a-base-de-carragelose\\\/\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-finalise-les-acquisitions-de-doliage-et-du-programme-de-developpement-dun-collyre-antiviral-a-base-de-carragelose\\\/\",\"name\":\"Nicox finalise les acquisitions de Doliage et du programme de d\u00e9veloppement d\u2019un collyre antiviral \u00e0 base de Carrag\u00e9lose\u00ae - Nicox\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#website\"},\"datePublished\":\"2014-09-25T18:42:57+00:00\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.nicox.com\\\/fr\\\/nicox-finalise-les-acquisitions-de-doliage-et-du-programme-de-developpement-dun-collyre-antiviral-a-base-de-carragelose\\\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/\",\"name\":\"Nicox\",\"description\":\"Visible Science\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#organization\",\"name\":\"Nicox\",\"url\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Nicox\"},\"image\":{\"@id\":\"https:\\\/\\\/www.nicox.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nicox finalise les acquisitions de Doliage et du programme de d\u00e9veloppement d\u2019un collyre antiviral \u00e0 base de Carrag\u00e9lose\u00ae - Nicox","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.nicox.com\/fr\/nicox-finalise-les-acquisitions-de-doliage-et-du-programme-de-developpement-dun-collyre-antiviral-a-base-de-carragelose\/","og_locale":"fr_FR","og_type":"article","og_title":"Nicox finalise les acquisitions de Doliage et du programme de d\u00e9veloppement d\u2019un collyre antiviral \u00e0 base de Carrag\u00e9lose\u00ae - Nicox","og_description":"Sophia Antipolis, France. \u00a0 Nicox S.A. (NYSE Euronext Paris : COX) annonce aujourd\u2019hui la r\u00e9alisation d\u00e9finitive de l\u2019acquisition de Doliage, une soci\u00e9t\u00e9 pharmaceutique fran\u00e7aise priv\u00e9e sp\u00e9cialis\u00e9e en ophtalmologie. Cette acquisition s\u2019inscrit dans la strat\u00e9gie de Nicox d\u2019\u00e9tablir une infrastructure commerciale dans les cinq principaux march\u00e9s europ\u00e9ens et apporte \u00e0 Nicox une entit\u00e9 \u00e9tablie et rentable [&hellip;]","og_url":"https:\/\/www.nicox.com\/fr\/nicox-finalise-les-acquisitions-de-doliage-et-du-programme-de-developpement-dun-collyre-antiviral-a-base-de-carragelose\/","og_site_name":"Nicox","article_published_time":"2014-09-25T18:42:57+00:00","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.nicox.com\/fr\/nicox-finalise-les-acquisitions-de-doliage-et-du-programme-de-developpement-dun-collyre-antiviral-a-base-de-carragelose\/#article","isPartOf":{"@id":"https:\/\/www.nicox.com\/fr\/nicox-finalise-les-acquisitions-de-doliage-et-du-programme-de-developpement-dun-collyre-antiviral-a-base-de-carragelose\/"},"author":{"name":"","@id":""},"headline":"Nicox finalise les acquisitions de Doliage et du programme de d\u00e9veloppement d\u2019un collyre antiviral \u00e0 base de Carrag\u00e9lose\u00ae","datePublished":"2014-09-25T18:42:57+00:00","mainEntityOfPage":{"@id":"https:\/\/www.nicox.com\/fr\/nicox-finalise-les-acquisitions-de-doliage-et-du-programme-de-developpement-dun-collyre-antiviral-a-base-de-carragelose\/"},"wordCount":344,"publisher":{"@id":"https:\/\/www.nicox.com\/fr\/#organization"},"articleSection":["Actualit\u00e9s","Actualit\u00e9s et M\u00e9dia"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.nicox.com\/fr\/nicox-finalise-les-acquisitions-de-doliage-et-du-programme-de-developpement-dun-collyre-antiviral-a-base-de-carragelose\/","url":"https:\/\/www.nicox.com\/fr\/nicox-finalise-les-acquisitions-de-doliage-et-du-programme-de-developpement-dun-collyre-antiviral-a-base-de-carragelose\/","name":"Nicox finalise les acquisitions de Doliage et du programme de d\u00e9veloppement d\u2019un collyre antiviral \u00e0 base de Carrag\u00e9lose\u00ae - Nicox","isPartOf":{"@id":"https:\/\/www.nicox.com\/fr\/#website"},"datePublished":"2014-09-25T18:42:57+00:00","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.nicox.com\/fr\/nicox-finalise-les-acquisitions-de-doliage-et-du-programme-de-developpement-dun-collyre-antiviral-a-base-de-carragelose\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.nicox.com\/fr\/#website","url":"https:\/\/www.nicox.com\/fr\/","name":"Nicox","description":"Visible Science","publisher":{"@id":"https:\/\/www.nicox.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.nicox.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.nicox.com\/fr\/#organization","name":"Nicox","url":"https:\/\/www.nicox.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.nicox.com\/fr\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Nicox"},"image":{"@id":"https:\/\/www.nicox.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":""}]}},"_links":{"self":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts\/6992","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/comments?post=6992"}],"version-history":[{"count":0,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/posts\/6992\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/media?parent=6992"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/categories?post=6992"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nicox.com\/fr\/wp-json\/wp\/v2\/tags?post=6992"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}